News
NVO
37.54
+0.59%
0.22
Cboe data shows mixed options sentiment in Novo Nordisk with shares down 0.47%
TipRanks · 7h ago
FDA Delays Regulatory Decision On Novo Nordisk Hemophilia Drug
Benzinga · 8h ago
J.P. Morgan Sticks to Their Hold Rating for Novo Nordisk (0QIU)
TipRanks · 12h ago
Weekly Report: what happened at NVO last week (0928-1002)?
Weekly Report · 14h ago
Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?
Simply Wall St · 15h ago
Novo Nordisk Could Raise Guidance Alongside Strong Results -- Market Talk
Dow Jones · 16h ago
NVO vs. LLY: Novo’s CEO Says Confidence Is Gone. Lilly Is Winning 7 in 10 New Seniors.
Barchart · 18h ago
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk?
The Motley Fool · 1d ago
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focus
Seeking Alpha · 1d ago
Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension
NASDAQ · 2d ago
Anthropic Commits $100 Million Behind AI Talent Push, Plans to Train 10,000 Engineers by 2027 as IPO Looms
Benzinga · 2d ago
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
Dow Jones · 3d ago
FDA extends review for Novo Nordisk's denecimig for hemophilia A
Seeking Alpha · 3d ago
Novo Provides Update On The Denecimig Biologics License Application In The US; The FDA Has Informed Novo That The BLA Review Of Denecimig For The Treatment Of Haemophilia A Is Still Ongoing; The FDA Has Not Communicated A New Timeline For Regulatory Action On The BLA
Benzinga · 3d ago
Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors
The Motley Fool · 3d ago
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data
Benzinga · 3d ago
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 3d ago
Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline
TipRanks · 3d ago
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
NASDAQ · 3d ago
Moderately bullish activity in Novo Nordisk with shares up 0.39%
TipRanks · 3d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.